What, Exactly, is Alcohol Use Disorder?
AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?
Solriamfetol Improves OSA-Related Cognitive Deficits Independent of Sleepiness Reduction
Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.
Topical Steroid Withdrawal vs Atopic Dermatitis Flare: Parsing the Differences with Brad Glick, DO, MPH
RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.
Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma
The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.
Lifestyle Interventions for Treatment and Remission of Prediabetes and T2D: There's a Guideline for That?
The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.
Key Updates in Atopic Dermatitis for Primary Care
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
Late-Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals
Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.
Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity
Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.
FDA Expands Label for Moderna's mRNA RSV Vaccine to Include At-Risk Adults Aged 18 to 59 Years
mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.
GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose
Your daily dose of the clinical news you may have missed.
Expanding Access to Atopic Dermatitis Treatments for Children: A Conversation with Elizabeth Swanson, MD
At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.
Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD
RAD 2025: Renowned AD investigator Kircik provides the history behind the classwide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.
Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50%
FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD
At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.
Cycling Linked to 19% Lower Risk of Dementia in Large UK Biobank Study
Cycling and mixed cycling were associated with a reduced risk of all-cause dementia, including of young onset, as well as increased hippocampal volume.
Guideline Topline: 14 Key Lifestyle Interventions to Treat, Prevent Type 2 Diabetes
These 14 recommendations from the American College of Lifestyle Medicine comprise the core of the first-ever guideline centered on lifestyle change as a first-line intervention.
New Study Highlights Lengthy Journey to Phase Out Low-Value Cancer Screenings in the US
Valid and accessible measures are needed to monitor low-value care practices and set benchmarks for de-implementation efforts, researchers reported.
High Discontinuation Rates of GLP-1 RA-Based Drugs Linked to Weight Loss Far Below Phase 3 Clinical Trials
High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.
A Close Look at Flexible Dosing Strategies for Atopic Dermatitis in Adults with Raj Chovatiya, MD, PhD, MSCI
RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.
The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.
